Molecular Glue DEL Screening to Produce Expansive Datasets for Systematic Hit Identification for High Value Therapeutic Targets

• Development and implementation of a molecular glue DEL screening platform at scale
• Leveraging PPI for targets with high unmet medical need that have proven limited or intractable for ligand finding efforts
• A combination of approaches increases confidence in hit calling for off-DNA synthesis of hits and leads to improved validation

Speakers:

Mat Sowa

Vice President, Lead Discovery

C4 Therapeutics Inc